DLL3 and glioblastoma: Rovalpituzumab tesirine (Rova-T), a Delta-like protein 3 (DLL3)-targeting antibody-drug conjugate, was evaluated for its efficacy in GBM as part of a broader phase I/II study on DLL3-positive tumors.